CRISPR Therapeutics AG [CRSP] stock prices are down -1.21% to $43.31 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The CRSP shares have lost -0.71% over the last week, with a monthly amount glided 6.96%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
CRISPR Therapeutics AG [NASDAQ: CRSP] stock has seen the most recent analyst activity on February 14, 2025, when Evercore ISI upgraded its rating to a Outperform and also boosted its price target to $99 from $60. Previously, TD Cowen upgraded its rating to Hold on February 12, 2025, and kept the price target unchanged to $35. On February 03, 2025, H.C. Wainwright initiated with a Buy rating and assigned a price target of $65 on the stock. Needham reiterated its Buy rating and decreased its price target to $84 on August 06, 2024. Rodman & Renshaw initiated its recommendation with a Buy and recommended $90 as its price target on August 02, 2024. In a note dated February 15, 2024, Wolfe Research initiated an Peer Perform rating.
The stock price of CRISPR Therapeutics AG [CRSP] has been fluctuating between $36.52 and $83.50 over the past year. Currently, Wall Street analysts expect the stock to reach $75.67 within the next 12 months. CRISPR Therapeutics AG [NASDAQ: CRSP] shares were valued at $43.31 at the most recent close of the market. An investor can expect a potential return of 74.72% based on the average CRSP price forecast.
Analyzing the CRSP fundamentals
The CRISPR Therapeutics AG [NASDAQ:CRSP] reported sales of 37.31M for trailing twelve months, representing a drop of -82.26%. Gross Profit Margin for this corporation currently stands at -2.27% with Operating Profit Margin at -12.74%, Pretax Profit Margin comes in at -9.9%, and Net Profit Margin reading is -10.0%. To continue investigating profitability, this company’s Return on Assets is posted at -0.16, Equity is -0.18 and Total Capital is -0.22. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 41.98 points at the first support level, and at 40.65 for the second support level. However, for the 1st resistance point, the stock is sitting at 44.19, and for the 2nd resistance point, it is at 45.07.
Ratios To Look Out For
It’s worth pointing out that CRISPR Therapeutics AG [NASDAQ:CRSP]’s Current Ratio is 22.07. On the other hand, the Quick Ratio is 22.07, and the Cash Ratio is 3.4. Considering the valuation of this stock, the price to sales ratio is 99.57, the price to book ratio is 1.92.
Transactions by insiders
Recent insider trading involved Greene John, Director, that happened on Feb 26 ’25 when 7000.0 shares were purchased. Chief Executive Officer, Kulkarni Samarth completed a deal on Feb 19 ’25 to sell 18360.0 shares. Meanwhile, Chief Executive Officer Kulkarni Samarth sold 11640.0 shares on Feb 18 ’25.
